Literature DB >> 2468355

Extensive argon laser photocoagulation in the treatment of proliferative diabetic retinopathy.

G W Aylward1, R V Pearson, J D Jagger, A M Hamilton.   

Abstract

A group of 20 patients (28 eyes) with proliferative retinopathy who required extensive argon laser photocoagulation to induce regression of new vessels is presented. The mean number of burns applied to each eye was 7225, with a maximum of 11,513. These were delivered in a mean of nine sessions over a mean period of 22.9 months. Twenty-five eyes (89%) had a final visual acuity of 6/18 or better. The remaining three eyes (11%) had severely reduced vision attributable to complications of proliferative diabetic retinopathy (traction retinal detachment involving the macula in two eyes and ischaemic maculopathy and a persistent vitreous haemorrhage in the third). Large amounts of confluent argon laser photocoagulation may be necessary for the elimination of new vessels in some patients, and it is our view that laser photocoagulation should be continued until regression of new vessels occurs. This is compatible with the retention of functional vision and good visual acuity.

Entities:  

Mesh:

Year:  1989        PMID: 2468355      PMCID: PMC1041690          DOI: 10.1136/bjo.73.3.197

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  11 in total

1.  Variation of energy density in argon laser photocoagulation.

Authors:  O Pomerantzeff; C L Schepens
Journal:  Arch Ophthalmol       Date:  1975-10

2.  Treatment of proliferative diabetic retinopathy. Long-term results of argon laser photocoagulation.

Authors:  H L Little
Journal:  Ophthalmology       Date:  1985-02       Impact factor: 12.079

3.  Peripheral retinal ablation in the treatment of proliferative diabetic retinopathy: a three-year interim report of a randomised, controlled study using the argon laser.

Authors:  B L Hercules; I I Gayed; S B Lucas; J Jeacock
Journal:  Br J Ophthalmol       Date:  1977-09       Impact factor: 4.638

4.  Estimation of the maximum number of argon laser burns possible in panretinal photocoagulation.

Authors:  C C Barr
Journal:  Am J Ophthalmol       Date:  1984-06       Impact factor: 5.258

5.  The efficacy of additional argon laser photocoagulation for persistent, severe proliferative diabetic retinopathy.

Authors:  A K Vine
Journal:  Ophthalmology       Date:  1985-11       Impact factor: 12.079

6.  Retinal laser damage thresholds as a function of image diameter.

Authors:  E S Beatrice; G D Frisch
Journal:  Arch Environ Health       Date:  1973-11

7.  Photocoagulation in diabetic retinopathy: III. Complications.

Authors:  C Townsend; A M Hamilton; H Cheng
Journal:  Int Ophthalmol Clin       Date:  1978

8.  PDR in juvenile onset diabetics: high-risk proliferative diabetic retinopathy in juvenile onset diabetics.

Authors:  L J Singerman; D T Weaver
Journal:  Retina       Date:  1981       Impact factor: 4.256

9.  Clinicopathologic correlation of xenon arc and argon laser photocoagulation. Procedure in human diabetic eyes.

Authors:  I H Wallow; M D Davis
Journal:  Arch Ophthalmol       Date:  1979-12

10.  Retinopathy risk factor regression after laser panretinal photocoagulation for proliferative diabetic retinopathy.

Authors:  B H Doft; G Blankenship
Journal:  Ophthalmology       Date:  1984-12       Impact factor: 12.079

View more
  7 in total

1.  Pascal panretinal laser ablation and regression analysis in proliferative diabetic retinopathy: Manchester Pascal Study Report 4.

Authors:  M M K Muqit; G R Marcellino; D B Henson; L B Young; G S Turner; P E Stanga
Journal:  Eye (Lond)       Date:  2011-08-05       Impact factor: 3.775

Review 2.  Current management of vitreous hemorrhage due to proliferative diabetic retinopathy.

Authors:  Jaafar El Annan; Petros E Carvounis
Journal:  Int Ophthalmol Clin       Date:  2014

3.  Characterisation of the neovascularisation process in diabetic retinopathy by means of fractal geometry: diagnostic implications.

Authors:  A Daxer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-12       Impact factor: 3.117

4.  Early vitrectomy for progressive diabetic proliferations covering the macula.

Authors:  R Grewing; U Mester
Journal:  Br J Ophthalmol       Date:  1994-06       Impact factor: 4.638

5.  Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture.

Authors:  J Fernando Arevalo; Juan G Sanchez; Andres F Lasave; Lihteh Wu; Mauricio Maia; Sergio Bonafonte; Miguel Brito; Arturo A Alezzandrini; Natalia Restrepo; Maria H Berrocal; Mario Saravia; Michel Eid Farah; Jans Fromow-Guerra; Virgilio Morales-Canton
Journal:  J Ophthalmol       Date:  2011-03-30       Impact factor: 1.909

6.  Intracameral bevacizumab and mitomycin C Trabeculectomy for eyes with neovascular glaucoma: a case series.

Authors:  Carlos Gustavo Vasconcelos de Moraes; Antonio Carlos Facio; José Humberto Costa; Roberto Freire Santiago Malta
Journal:  J Ocul Biol Dis Infor       Date:  2009-03-31

7.  A proposed new classification for diabetic retinopathy: the concept of primary and secondary vitreopathy.

Authors:  Arvind Kumar Dubey; Pran Nath Nagpal; Shobhit Chawla; Benu Dubey
Journal:  Indian J Ophthalmol       Date:  2008 Jan-Feb       Impact factor: 1.848

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.